Showing results (81-90 of 217) with videos related to
Sort By:
Pageof 22
Thoracic Cancer|August 16, 2022
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancerAlessandra Buja, Giulia Pasello, Marco Schiavon, et al.Scientific Reports|May 11, 2019
A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncologyOlivia Candini, Giulia Grisendi, Elisabetta Manuela Foppiani, et al.Cancers|May 14, 2025
Patterns of Comorbidities in Lung Cancer Patients and SurvivalAlessandra Buja, Marcello Di Pumpo, Massimo Rugge, et al.Breast Cancer Research and Treatment|January 11, 2016
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancerJoanne L Blum, Anthony Gonçalves, Noa Efrat, et al.Frontiers in Public Health|November 3, 2025
Healthcare costs of cutaneous melanoma according to comorbidity patterns: a population-based study from the Regional Cancer Registry of the Veneto RegionAlessandra Buja, Fortunato Cassalia, Massimo Rugge, et al.Oncotarget|August 24, 2015
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killingMalvina Prapa, Sara Caldrer, Carlotta Spano, et al.Scientific Reports|February 1, 2020
Author Correction: A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncologyOlivia Candini, Giulia Grisendi, Elisabetta Manuela Foppiani, et al.Tumori|February 8, 2013
Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution seriesFederica Bertolini, Elena Zunarelli, Caterina Baraldi, et al.BMC Cancer|November 26, 2025
Impact of comorbidities on survival in melanoma patientsAlessandra Buja, Fortunato Cassalia, Massimo Rugge, et al.BMJ Open|February 26, 2026
Predictors of unplanned 30-day hospital readmission: a retrospective cohort study in north-east ItalyGino Sartor, Marco Fusco, Marzio Milana, et al.Pageof 22